Back to Search
CAMILLE BEDROSIAN, MD
MD
Internal Medicine Physician
NPI: 1487715546Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
153940(MA)30889(NC)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
153940(MA)30889(NC)
Research & Publications (7)
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
PMID 19228743·Clin Cancer Res·2009
3-trial
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
PMID 18451242·Clin Cancer Res·2008
3-trial
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
PMID 18202410·J Clin Oncol·2008
3-trial
The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.
PMID 12558777·Haemophilia·2003
3-trial
Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients.
PMID 11449336·Semin Hematol·2001
3-trial
Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients.
PMID 11449335·Semin Hematol·2001
8-other
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters.
PMID 10899677·Oral Oncol·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139 - Phone
- (617) 494-0400
Quick Facts
- NPI
- 1487715546
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 1
- Publications
- 7
Are you this provider?
Claim Your Profile